In 2023, the opportunities in the pharmaceutical sector look at two keywords

【Pharmaceutical Network Market Analysis】Recently, the pharmaceutical sector is active, especially the individual stocks related to analgesia and antipyretic continued to rise, although the pharmaceutical and biological sector has fallen since December 19, the sector has been differentiated, and the concept stocks such as Xinhua Pharmaceutical have generally fallen for many days, but in the context of policy optimization, the low point of the pharmaceutical industry has passed, so the pharmaceutical market is still optimistic
about the industry.
Looking forward to 2023, Soochow Securities believes in the research report that the opportunities of the pharmaceutical sector look at two keywords, one is "anti-epidemic" and the other is "post-epidemic"
.
On the one hand, "anti-epidemic" related products and anti-cold drugs and their industrial chain are still expected to benefit, including anti-cold drugs (including traditional Chinese medicine) with high performance certainty, retail pharmacies, household equipment such as oxygen generators, antigen testing, etc
.
Soochow Securities Research reported that the public's awareness of self-protection has increased, and the demand for epidemic prevention related drugs in pharmacy channels has increased
.
Oxygen generators, antigen testing, and sequential vaccination of vaccines are important parts of the fight against the epidemic, and related targets have also benefited
to a certain extent.
On the other hand, there are three main lines of "post-epidemic", one is four types of enterprises whose demand recovers after the epidemic eases: consumer medical care, scientific research services, clinical CRO companies, and export-oriented companies represented by medical services and medical beauty; The second is the "post-epidemic" outpatient and inpatient volume replenishment, and the hospital's drugs and equipment, IVD plates just need to be increased
.
Focus on three directions: perioperative drugs, in vitro diagnosis, and high-value consumables
.
Surgical recovery + severe disease increased, perioperative drug Three Musketeers anesthesia + analgesia + parenteral nutrition particularly benefited
.
Domestic chemiluminescence was accelerated
against the background of DRGs.
In addition, high-value consumables for hospital-related surgeries will usher in rapid development; The third is the innovative drug sector
.
Soochow Securities believes that driven by the XBI index, a number of favorable policies, beautiful product data readout, etc.
, the market's attention to innovative drugs and industrial chain has increased significantly, and the company's short-term catalysts can become potential valuation factors
.
The review found that the current macro policy and the Fed's interest rate hike expectations are limited, the global innovative drug investment and financing rebound trend is showing, the certainty of the marginal warming of pharmaceutical policy is enhanced, and multiple indicators indicate that innovative drug companies and their industrial chain companies will usher in a big beta market
in 2023 。 For investment opportunities in 2023, some pharmaceutical industry analysts also mentioned the segment of innovative drugs, which believes that whether it is the simple renewal of medical insurance or the renegotiation of medical insurance, the support of policies for innovative drugs is relatively large, and more importantly, after more than one year of adjustment, there is currently a more obvious value space
in the field of innovative drugs.
In a recent research report released by GF Securities, it was also pointed out that driven by the new policy, pharmaceutical innovation and upgrading have become the consensus
of the industry and capital market.
High-quality innovation and internationalization will become the main theme, China has been born biotech (early molecular license out) that can be among the global innovative drug industry chain, thanks to the domestic basic science engineer dividend, the future will be more and more, but also need enterprises to have global development and even commercialization capabilities
.
With the upgrading of domestic innovation and internationalization, R&D investment is expected to increase rapidly; Under the influence of the deepening of domestic medical reform on the income side, the valuation model of innovative enterprises should be adjusted
accordingly.
It is recommended to focus on the R&D strength and growth trend
of innovative drug companies.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.